Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Thanks Xeno
Could someone please upload the Swedish chat board. I seem to have lost it and this could now getting interesting for Beowulf. Thank you.
The Merck announcement was at 7am NY time which coincides with 11am London Time. That was the moment that the Synairgen share price started to rocket.
The Merck drug isn't that great and they do not expect to complete the Phase 3 trial until Autumn. This represents a good read-across for Synairgen getting an early EUA
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734101/
The treatment described in this 6 month old research paper relates to the use in France of the Novartis Extavia Interferon Beta 1b product, in a cobbled-together inhalation format. It is worth reading again as we await Olivier Veran (Health Minister of France) announcing trial results, which are expected any day now. As far as I am aware Synairgen has the patent, so the trial readout should be very positive for Synairgen.
I think this might explain RM's comment made in two recent radio stations, that breathless outpatients will be the subject of an international trial. This would be an extension of ACTIV2.
This is 30 minutes of AN with a good Q&A. Starts at 1:23:27 to 1:54:00
http://amatiglobal.com/videos.php?id=26
https://finance.yahoo.com/news/1-u-fda-gives-emergency-215546945.html
Slightly more info in this link
https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.14898
Downloaded from twitter. This is the report on the China study found in the pdf document. The section of particular interest is the discussion towards the end of this report.
https://www.fda.gov/drugs/drug-safety-and-availability/statement-leronlimab
Good find Sheephatch